The treatment of advanced prostate cancer with ketoconazole. Safety issues

Drug Safety

Volumn 20, Issue 5, 1999, Pages 451-458

  Bok, Robert A ^a   Small, Eric J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ASTEMIZOLE; CISAPRIDE; COUMARIN; INDINAVIR; KETOCONAZOLE; LOW DENSITY LIPOPROTEIN; NELFINAVIR; SAQUINAVIR; TERFENADINE; TRIAZOLAM;

ABDOMINAL PAIN; ADRENAL INSUFFICIENCY; ADVANCED CANCER; ANOREXIA; ASTHENIA; CARDIOVASCULAR DISEASE; DROWSINESS; DRY SKIN; EDEMA; ENDOCRINE DISEASE; FATIGUE; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HEADACHE; HEPATITIS; HUMAN; HYPERPIGMENTATION; HYPERTENSION; HYPOCALCEMIA; IMPOTENCE; LIVER TOXICITY; MALE; MUCOSA INFLAMMATION; NAIL DYSTROPHY; NAUSEA; PRIORITY JOURNAL; PROSTATE CANCER; PRURITUS; RASH; REVIEW; SKIN DISEASE; VERTIGO; VOMITING; XEROSTOMIA;

ANIMALS; ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS; HUMANS; KETOCONAZOLE; MALE; PROSTATIC NEOPLASMS;

EID: 0032923120     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199920050-00005     Document Type: Review

References (38)

1. Trachtenberg J, Halpern N, Pont A. Ketoconazole: a novel and rapid treatment for advanced prostatic cancer. J Urol 1983; 130 (1): 152-3
2. Amery WK, De Coster R, Caers I, Ketoconazole: from an antimycotic to a drug for prostate cancer. Drug Dev Res 1986; 9: 269-307
3. Trachtenberg J, Pont A. Ketoconazole therapy for advanced prostate cancer. Lancet 1984; 11 (8400): 433-5.
4. Mahler C, Verhelst J, Denis L. Ketoconazole and liarozole in the treatment of advanced prostatic cancer. Cancer 1993; 71 (3 Suppl.): 1068-73
5. Small FJ, Baron AD, Fippin L, et al. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol 1997; 157 (4): 1204-7
6. Small EJ, Baron A, Bok R. Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma. Cancer 1997; 80 (9): 1755-9
7. Rodriguez RJ, Acosta D, Jr. Comparison of ketoconazole- and fluconazole-induced hepatotoxicity in a primary culture system of rat hepatocytes. Toxicology 1995, 96 (2): 83-92
8. Van den Bossche H, Willemsens G, Cools W, et al. In vitro and in vivo effects of the antimycotic drug ketoconazole on sterol synthesis. Antimicrob Agents Chemother 1980; 17: 922-8
9. Willemsens G, Cools W, Van den Bossche H. Effect of miconazole and ketoconazole on sterol synthesis in subcellular fraction of yeast and mammalian cells. In: Van den Bossche H, editor. The host-invader interplay. New York: Elsevier North-Holland, 1980: 691-4
10. Geller J, de la Vega DJ, Albert JD, et al. Tissue dihydrolestosterone levels and clinical response to hormonal therapy in patients with advanced prostate cancer. J Clin Endocrinol Metab 1984; 58 (1): 36-40
11. De Coster R, Wouters W, Bruynseels J. P450-dependent enzymes as targets for prostate cancer therapy. J Steroid Biochem Mol Biol 1996; 56 (1-6 Spec No.): 133-43
12. Sarver RG, Dalkin BL, Ahmann FR. Ketoconazole-induced adrenal crisis in a patient with metastatic prostatic adenocarcinoma: case report and review of the literature. Urology 1997; 49 (5): 781-5
13. Van Wauwe JP, Coene MC, Goossens J, et al. Ketoconazole inhibits the in vitro and in vivo metabolism of all-transretinoic acid. J Pharmacol Exp Ther 1988; 245: 718-22
14. Williams G. Kerle DJ, Ware H, et al. Objective responses to ketoconazole therapy in patients with relapsed progressive prostatic cancer. Br J Urol 1986; 58 (1): 45-51
15. Shaw MA, Nicholls PJ, Smith HJ. Aminoglutethimide and ketoconazole: historical perspectives and future prospects. J Steroid Biochem 1988; 31 (1): 137-46
16. Muscato JJ, Ahmann TA, Johnson KM, et al. Optimal dosing of ketoconazole and hydrocortisone leads to long responses in hormone refractory prostate cancer [abstract]. Proceedings of the American Society of Clinical Oncology; 1994 May 14-17: Dallas. J Clin Oncol 1994; 13: 229
17. Trump DL, Havlin KH, Messing EM, et al. High-dose ketoconazole in advanced hormone-refractory prostate cancer: endocrinologic and clinical effects. J Clin Oncol 1999; 7: 1093-8
18. Jubelirer SJ, Hogan T. High dose ketoconazole for the treatment of hormone refractory metastatic prostate carcinoma: 16 cases and review of the literature. J Urol 1999; 142 (1): 89-91
19. Lake-Bakaar G, Scheuer PJ, Sherlock S. Hepatic reactions associated with ketoconazole in the United Kingdom. BMJ (Clin Res Ed) 1987; 294 (6569): 419-22
20. Hay RJ. Ketoconazole in the treatment of fungal infection: clinical and laboratory studies. Am J Med 1983; 74 (1B): 16-9
21. Janssen PA, Symoens JE. Hepatic reactions during ketoconazole treatment. Am J Med 1983; 74 (1B): 80-5
22. Sonino N. The use of ketoconazole as an inhibitor of steroid production. N Engl J Med 1987; 317 (13): 812-8
23. Bercoff E, Bernuau J. Degott C, et al. Ketoconazole-induced fulminant hepatitis. Gut 1985; 26 (6): 636-8
24. Stricker BH, Blok AP, Bronkhorst FB, et al. Ketoconazole-associated hepatic injury: a clinicopathological study of 55 cases. J Hepatol 1986; 3 (3): 399-406
25. Benson GD, Anderson PK, Combes B, et al. Prolonged jaundice following ketoconazole-induced hepatic injury. Dig Dis Sci 1988; 33 (2): 240-6
26. Rodriguez RJ. Acosta D, Jr. N-deacetyl ketoconazole-induced hepatotoxicity in a primary culture system of rat hepatocytes. Toxicology 1997; 117 (2-3): 123-31
27. Polsen JA, Cohen PR, Sella A. Acquired cutaneous adherence in patients with androgen-independent prostate cancer receiving ketoconazole and doxorubicin: medication-induced sticky skin. J Am Acad Dermatol 1995; 32 (4): 571-5
28. Sella A, Kilbourn R, Amato R, et al. Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. J Clin Oncol 1994; 12 (4): 683-8
29. Aabo K, De Coster R. Hypertension during high-dose ketoconazole treatment: a probable mineralocorticosteroid effect [letter]. Lancet 1987; II (8559): 637-8
30. Gylling H, Vanhanen H, Miettinen TA, Effects of ketoconazole on cholesterol precursors and low density lipoprotein kinetics in hypercholesterolemia. J Lipid Res 1993; 34 (1): 59-67
31. Kraemer FB, Pont A. Inhibition of cholesterol synthesis by ketoconazole. Am J Med 1986; 80 (4): 616-22
32. Pont A, Williams PL, Loose DS, et al. Ketoconazole blocks adrenal steroid synthesis. Ann Intern Med 1982; 97 (3): 370-2
33. Trachtenberg J. The effects of ketoconazole on testosterone production and normal and malignant androgen dependent tissues of the adult rat. J Urol 1984; 132 (3): 599-601
34. White MC, Kendall-Taylor P. Adrenal hypofunction in patients taking ketoconazole [letter]. Lancet 1985; 1 (8419): 44-5
35. Tucker Jr WS, Snell BB, Island DP, et al. Reversible adrenal insufficiency induced by ketoconazole. J Am Med Assoc 1985; 253 (16): 2413-4
36. Best TR, Jenkins JK, Murphy FY, et al. Persistent adrenal insufficiency secondary to low-dose ketoconazole therapy. Am J Med 1987; 82 (3 Spec No.): 676-80
37. DeFelice R, Johnson DG, Galgiani JN. Gynaecomastia with ketoconazole. Antimicrob Agents Chemother 1981; 19 (6): 1073-4
38. Novack GD. Ocular toxicology. Curr Opin Ophthalmol 1994; 5 (6): 110-4